Chia Tai-Tianqing Pharmaceutical Group

Chia Tai-Tianqing Pharmaceutical Group (CTTQ) is a leading Chinese pharmaceutical company and a core subsidiary of Sino Biopharmaceutical Limited. Headquartered in Lianyungang, the company is a dominant player in the domestic market, particularly recognized for its leadership in liver disease and oncology treatments. CTTQ operates extensive R&D centers in Nanjing and Shanghai, focusing on the development of both innovative new chemical entities and high-end biologics. Its commercial portfolio features blockbuster drugs like the multi-kinase inhibitor Anlotinib and the PD-1 inhibitor Penpulimab. The company maintains a vast pipeline across multiple therapeutic areas, supported by strategic global collaborations and advanced manufacturing capabilities.